<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205074</url>
  </required_header>
  <id_info>
    <org_study_id>METH-EX-610- HMO - CTIL</org_study_id>
    <nct_id>NCT01205074</nct_id>
  </id_info>
  <brief_title>¹³C-Methacetin Breath Test (MBT) Methodology Study</brief_title>
  <official_title>¹³C-Methacetin Breath Test (MBT) Methodology Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <brief_summary>
    <textblock>
      Several factors will be tested to see if they have an influence on the methacetin breath test&#xD;
      results. Each one of the factors has been raised as a possible source of distortion of the&#xD;
      MBT result.&#xD;
&#xD;
      I. Variability between same tests on same subject MBT. Repeatability will be tested in both&#xD;
      healthy individuals and patients with chronic liver disease.&#xD;
&#xD;
      II. COPD - Chronic obstructive pulmonary disease is a leading cause of death worldwide, and&#xD;
      can potentially have an effect on the MBT since the breath test is based on CO2 production&#xD;
      and these subjects may have abnormal CO2 production.&#xD;
&#xD;
      III. Smoking- 13C Methacetin is metabolized by healthy hepatocytes reflecting hepatic&#xD;
      microsomal function of CYP1A2, and smoking may cause induction of CYP1A2. Furthermore,&#xD;
      internal preliminary data has shown signs that there is an influence of smoking on the MBT&#xD;
      ranges.&#xD;
&#xD;
      IV. Age- Empirical data on several hundred subjects with chronic liver disease has shown that&#xD;
      age is a significant factor in determining the probability of disease severity and&#xD;
      preliminary data in normal subjects have shown changes in MBT with age.. Therefore, the&#xD;
      effect of age has to be elucidated in an orderly fashion.&#xD;
&#xD;
      V. CYP450 1A2 Inhibitors- Several drugs and food items inhibit CYP450 1A2 and may affect the&#xD;
      MBT.&#xD;
&#xD;
      VI. Alcohol - Alcohol ingestion leads to induction of hepatic CYP and at a later stage to&#xD;
      inhibition due to liver damage. Acute alcohol ingestion may therefore effect MBT results.&#xD;
&#xD;
      VII. Beta-blockers - beta blocker are affecting portal hypertension and may affect hepatic&#xD;
      blood flow and thereby the outcome of the methacetin breath test.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <number_of_arms>6</number_of_arms>
  <condition>Healthy Subjects</condition>
  <condition>Chronic Liver Disease</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Repeatability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Smokers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP450 1A2 Inhibitors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cirrhosis Beta Blockers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>13C Methacetin Breath Test</intervention_name>
    <arm_group_label>Alcohol</arm_group_label>
    <arm_group_label>COPD</arm_group_label>
    <arm_group_label>CYP450 1A2 Inhibitors</arm_group_label>
    <arm_group_label>Cirrhosis Beta Blockers</arm_group_label>
    <arm_group_label>Repeatability</arm_group_label>
    <arm_group_label>Smokers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Grape fruit juice</intervention_name>
    <arm_group_label>CYP450 1A2 Inhibitors</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Non selective beta blocker - Propranolol</intervention_name>
    <arm_group_label>Cirrhosis Beta Blockers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <arm_group_label>Alcohol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion Criteria - General&#xD;
&#xD;
          -  Adult subjects with 18 years of age or older&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urinary hCG pregnancy&#xD;
             test within 7 days prior to enrollment. During the study these women must use 2&#xD;
             methods of contraception.&#xD;
&#xD;
          -  Subject has given written informed consent, prior to any study related procedure not&#xD;
             part of the subject's normal medical care, with the understanding that consent may be&#xD;
             withdrawn at any time without prejudice to future medical care.&#xD;
&#xD;
        Exclusion Criteria - General&#xD;
&#xD;
          -  Severe heart, pulmonary or renal disease.&#xD;
&#xD;
          -  Patient has previous surgical bypass surgery for morbid obesity&#xD;
&#xD;
          -  Patient has extensive small bowel resection&#xD;
&#xD;
          -  Any major surgery in the past 3 months.&#xD;
&#xD;
          -  Patient is a recipient of any organ transplant&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Patient allergic to acetaminophen&#xD;
&#xD;
          -  Patients who are taking hepatotoxic drugs&#xD;
&#xD;
          -  Patient, based on the opinion of the investigator, should not be enrolled into this&#xD;
             study.&#xD;
&#xD;
          -  Patients unable or unwilling to sign informed consent&#xD;
&#xD;
          -  Patients that are participating in other clinical trials evaluating experimental&#xD;
             treatments or procedures or have participated in a clinical trial in the past 3&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria (Day of MBT-general)&#xD;
&#xD;
          -  Patient has not fasted for 8 hours.&#xD;
&#xD;
          -  Patient has smoked on the day of the test.&#xD;
&#xD;
          -  Patient that has taken drugs that can interfere with methacetin metabolism:&#xD;
             fluvoxamine, amiodarone, ciprofloxacin, cimetidine, rifampin, carbamazepine within the&#xD;
             last 24 hours.&#xD;
&#xD;
          -  Patient has taken Tylenol or any other acetaminophen related medications within the&#xD;
             past 24 hours.&#xD;
&#xD;
          -  Patients that received any new medication in the last 48 hours.&#xD;
&#xD;
          -  Patients that still suffer from any previous clinical intervention (e.g. biopsy)&#xD;
&#xD;
          -  Have not consumed alcohol 24 hours prior the MBT and not consume on a regular basis&#xD;
             more than 40gr for male and 20gr for female per day.&#xD;
&#xD;
        Inclusion Criteria (Repeatability):&#xD;
&#xD;
        Healthy Subjects:&#xD;
&#xD;
          -  No known liver disease&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
          -  BMI =20-25 kg/m2&#xD;
&#xD;
          -  Normal liver enzymes (ALT &lt; 40 U/L for men, &lt; 30 U/L for women)&#xD;
&#xD;
          -  Not taking any medications&#xD;
&#xD;
          -  No known on-going chronic medical conditions (apart from allergy or orthopaedic&#xD;
             conditions not requiring chronic therapy).&#xD;
&#xD;
          -  Normal abdominal ultrasound (US)&#xD;
&#xD;
        Cirrhotics:&#xD;
&#xD;
          -  Diagnosis of cirrhosis by liver biopsy&#xD;
&#xD;
          -  Or strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of&#xD;
             cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver,&#xD;
             small right lobe span or palpable splenomegaly), and/or radiological evidence of&#xD;
             cirrhosis (by abdominal sonography, computer assisted axial tomography, or magnetic&#xD;
             resonance imaging, showing a nodular liver and/or portosystemic collaterals with&#xD;
             portal vein patency and/or ascites and/or splenomegaly, and/or colloid shift on a&#xD;
             colloid-isotope liver-spleen scan), and/or laboratory variables (platelets&#xD;
             &lt;100,000/mm3, albumin&lt; 3.5g/dL, or INR &gt;1.3)&#xD;
&#xD;
        Chronic Liver Patient (non cirrhotic):&#xD;
&#xD;
        Patient who has been diagnosed with chronic liver disease for more than 6 months.&#xD;
&#xD;
        Inclusion Criteria (COPD):&#xD;
&#xD;
          -  No known liver disease&#xD;
&#xD;
          -  BMI 20- 25 kg/m2&#xD;
&#xD;
          -  Normal liver enzymes (ALT &lt; 40 U/L for men, &lt; 30 U/L for women)&#xD;
&#xD;
          -  Patients with a COPD exacerbation with elevated PCO2 levels (&gt; 50 mmHg)&#xD;
&#xD;
          -  Without clinically overt right heart failure&#xD;
&#xD;
          -  Ceased smoking for at least one month&#xD;
&#xD;
          -  No other overt clinical dysfunction of major organ system&#xD;
&#xD;
        Inclusion criteria (Smoker):&#xD;
&#xD;
        Smokers:&#xD;
&#xD;
          -  No known liver disease&#xD;
&#xD;
          -  Active smoker of at least 10 cigarettes/day (stable number of cigarettes during past&#xD;
             month - not currently trying to quit).&#xD;
&#xD;
          -  BMI 20- 25 kg/m2&#xD;
&#xD;
          -  Normal liver enzymes (ALT &lt; 40 U/L for men, &lt; 30 U/L for women)&#xD;
&#xD;
          -  Not taking any medications&#xD;
&#xD;
          -  No known chronic medical conditions&#xD;
&#xD;
        Inclusion criteria (CYP450 1A2 inhibitors):&#xD;
&#xD;
        Healthy Subjects:&#xD;
&#xD;
          -  No known liver disease&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
          -  BMI 20- 25 kg/m2&#xD;
&#xD;
          -  Normal liver enzymes (ALT &lt; 40 U/L for men, &lt; 30 U/L for women)&#xD;
&#xD;
          -  Not taking any medications&#xD;
&#xD;
          -  No known chronic medical conditions (allergy or orthopaedic condition not requiring&#xD;
             chronic therapy allowed).&#xD;
&#xD;
          -  Normal abdominal US&#xD;
&#xD;
        Cirrhotic subjects:&#xD;
&#xD;
          -  Diagnosis of cirrhosis by liver biopsy&#xD;
&#xD;
          -  Or strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of&#xD;
             cirrhosis (e.g. peripheral edema or varices, palpable hard left lobe of the liver,&#xD;
             small right lobe span or palpable splenomegaly), and/or radiological evidence of&#xD;
             cirrhosis (by abdominal sonography, computer assisted axial tomography, or magnetic&#xD;
             resonance imaging, showing a nodular liver and/or portosystemic collaterals with&#xD;
             portal vein patency and/or ascites and/or splenomegaly, and/or colloid shift on a&#xD;
             colloid-isotope liver-spleen scan), and/or laboratory variables (platelets&#xD;
             &lt;100,000/mm3, albumin&lt; 3.5g/dL, or INR &gt;1.3)&#xD;
&#xD;
          -  Not receiving medication which is metabolized by CYP450 1A2&#xD;
&#xD;
        Inclusion criteria (Beta Blockers):&#xD;
&#xD;
          -  Diagnosis of cirrhosis (by liver biopsy or clinical diagnosis):&#xD;
&#xD;
        Strong suspicion of cirrhosis by accepted criteria for the clinical diagnosis of cirrhosis&#xD;
        (e.g. peripheral edema or varices, palpable hard left lobe of the liver, small right lobe&#xD;
        span or palpable splenomegaly), and/or radiological evidence of cirrhosis (by abdominal&#xD;
        sonography, computer assisted axial tomography, or magnetic resonance imaging, showing a&#xD;
        nodular liver and/or portosystemic collaterals with portal vein patency and/or ascites&#xD;
        and/or splenomegaly, and/or colloid shift on a colloid-isotope liver-spleen scan), and/or&#xD;
        laboratory variables (platelets &lt;100,000/mm3, albumin&lt; 3.5g/dL, or INR &gt;1.3)&#xD;
&#xD;
          -  Naive to Beta Blockers - with a clinical indication for initiating therapy (eg.&#xD;
             esophageal varices, portal hypertensive gastropathy)&#xD;
&#xD;
          -  Resting pulse &gt; 60 beats per minute&#xD;
&#xD;
          -  Non smoker&#xD;
&#xD;
        Inclusion criteria (Alcohol):&#xD;
&#xD;
          -  No known liver disease&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
          -  BMI 20- 25 kg/m2&#xD;
&#xD;
          -  Normal liver enzymes (ALT &lt; 40 U/L for men, &lt; 30 U/L for women)&#xD;
&#xD;
          -  Not taking any medications&#xD;
&#xD;
          -  No known chronic medical conditions. (Allergy or orthopaedic condition not requiring&#xD;
             chronic therapy allowed).&#xD;
&#xD;
          -  Normal abdominal US&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General&#xD;
&#xD;
          -  Severe heart, pulmonary or renal disease.&#xD;
&#xD;
          -  Patient has previous surgical bypass surgery for morbid obesity&#xD;
&#xD;
          -  Patient has extensive small bowel resection&#xD;
&#xD;
          -  Any major surgery in the past 3 months.&#xD;
&#xD;
          -  Patient is a recipient of any organ transplant&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Patient allergic to acetaminophen&#xD;
&#xD;
          -  Patients who are taking hepatotoxic drugs&#xD;
&#xD;
          -  Patient, based on the opinion of the investigator, should not be enrolled into this&#xD;
             study.&#xD;
&#xD;
          -  Patients unable or unwilling to sign informed consent&#xD;
&#xD;
          -  Patients that are participating in other clinical trials evaluating experimental&#xD;
             treatments or procedures or have participated in a clinical trial in the past 3&#xD;
             months.&#xD;
&#xD;
        Exclusion Criteria (Day of MBT-general)&#xD;
&#xD;
          -  Patient has not fasted for 8 hours.&#xD;
&#xD;
          -  Patient has smoked on the day of the test.&#xD;
&#xD;
          -  Patient that has taken drugs that can interfere with methacetin metabolism:&#xD;
             fluvoxamine, amiodarone, ciprofloxacin, cimetidine, rifampin, carbamazepine within the&#xD;
             last 24 hours.&#xD;
&#xD;
          -  Patient has taken Tylenol or any other acetaminophen related medications within the&#xD;
             past 24 hours.&#xD;
&#xD;
          -  Patients that received any new medication in the last 48 hours.&#xD;
&#xD;
          -  Patients that still suffer from any previous clinical intervention (e.g. -&#xD;
&#xD;
          -  Have not consumed alcohol 24 hours prior the MBT and not consume on a regular basis&#xD;
             more than 40gr for male and 20gr for female per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Liver Unit Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <study_first_submitted>September 16, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2012</last_update_posted>
  <keyword>Patients with chronic liver disease and cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

